Inotuzumab ozogamicin
- Generic Name
- Inotuzumab ozogamicin
- Brand Names
- Besponsa
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 635715-01-4
- Unique Ingredient Identifier
- P93RUU11P7
- Background
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting ...
- Indication
Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).
- Associated Conditions
- Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06554626
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 21
- Registration Number
- NCT06427330
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 53
- Registration Number
- NCT06387121
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06287229
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-11-02
- Target Recruit Count
- 42
- Registration Number
- NCT06087419
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
- Conditions
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Sheng-Li Xue, MD
- Target Recruit Count
- 42
- Registration Number
- NCT05940961
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT05748171
- Locations
- 🇫🇷
Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France
🇩🇪Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Schleswig-holstein, Germany
🇩🇰Rigshospitalet, Copenhagen, Hovedstaden, Denmark
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05687032
- Locations
- 🇨🇳
The First Hospital of Harbin, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05645718
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT05597085
- Locations
- 🇮🇳
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi, India
🇮🇳Fortis Memorial Research Institute, Gurugram, Haryana, India
🇮🇳Tata Medical Center, Kolkata, WEST Bengal, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.